Objective:To retrieve, analyze and summarize the best evidence for obesity management in patients with polycystic ovary syndrome (PCOS) , so as to provide a reference for medical and nursing staff.Methods:The relevant articles on obesity management in PCOS were systematically searched in domestic and foreign databases, and the search time limit was from the establishment of the database to January 31, 2022. The article included clinical decisions, guidelines, evidence summaries, systematic reviews, and expert consensus. Two investigators with evidence-based training independently reviewed the included article and conducted evidence extraction.Results:A total of 11 articles were included, including 2 clinical decisions, 6 guidelines, and 3 expert consensuses. Finally, 30 pieces of evidence were summarized, covering 8 aspects of monitoring indicators and screening, lifestyle intervention, diet management, exercise management, drug management, adolescent PCOS management, bariatric surgery, and pregnancy-related management.Conclusions:This study summarizes the best evidence for obesity management in PCOS patients. Medical and nursing staff should give patients individualized obesity management based on actual clinical conditions and evidence-based evidence.

The protein p53 plays an important role in the regulation of DNA repair, cell cycle arrest, apoptosis, senescence, autophagy and metabolism. MDM2 and MDM4 are the key negative regulatory proteins of p53. Inhibition of MDM2 and MDM4 has become a research hotspot in cancer therapy. Currently, seven MDM2 inhibitors(RG7112, MI-77301, RG7388, AMG232, CGM097, MK-8242, DS-3032b)and one MDM2/MDM4 dual inhibitor(ALRN-6924)have entered clinical trials. This paper highlights small molecule discovery, pharmacological activities and clinical research advances of MDM2 inhibitors in clinical trials, in addition, this review introduces research advances of MDM2/MDM4 dual inhibitors.

Psychological factors have become significant contributors to the onset and progression of insomnia. This article explored the treatment of insomnia from the perspective of “liver governs wei qi （defensive qi）”. The concept of “liver governs wei qi （defensive qi）” is summarized in three aspects， firstly， the liver assists the spleen and stomach in transformation and transportation， governing the generation of wei qi； secondly， the liver aids lung qi diffusion and dispersion， governing the distribution of wei qi； thirdly， the liver regulates circadian rhythms， governing the circulation of wei qi. It is proposed that the clinical treatment of insomnia should focus on the following methods： for regulating the liver to harmonize the five viscera， and facilitate the circulation of wei qi， medicinals entering the liver channel include Chaihu （Bupleuri radix）， Baishao （Paeoniae Radix Alba）， Zhizi （Gardeniae Fructus）， and Suanzaoren （Ziziphi Spinosae Semen） could be commonly used； for nourishing the liver， the treatment should align with the day-night rhythm， and herbs such as Baihe （Lilium）， Hehuan （Albizia julibrissin）， and Yejiaoteng （Polygoni multiflori caulis） are commonly used； for soothing the liver and address both mental and physical health to calm wei qi， treatment should advocate verbal counseling， psychological regulation， and health education. Ultimately， this treatment approach can free liver qi to flow， soothe qi movement， restore the motion of wei qi， regulate during day and night， balance yin and yang， and resolve insomnia effectively.